APA (7th ed.) Citation

M, S., J, R., M, E., F, D., L, N., MV, K., . . . MA, M. (2023). Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial. Annals of the American Thoracic Society, 20(8), 1144. https://doi.org/10.1513/AnnalsATS.202208-684OC

Chicago Style (17th ed.) Citation

M, Stahl, et al. "Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 Through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial." Annals of the American Thoracic Society 20, no. 8 (2023): 1144. https://doi.org/10.1513/AnnalsATS.202208-684OC.

MLA (9th ed.) Citation

M, Stahl, et al. "Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 Through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial." Annals of the American Thoracic Society, vol. 20, no. 8, 2023, p. 1144, https://doi.org/10.1513/AnnalsATS.202208-684OC.